NCT00645710View on ClinicalTrials.gov

Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 11, 2005

Primary Completion Date

February 7, 2018

Study Completion Date

February 7, 2018

Conditions
Liver MetastasesRecurrent Colon CancerRecurrent Rectal CancerStage IV Colon CancerStage IV Rectal Cancer
Interventions
DRUG

gemcitabine hydrochloride

Given IV

DRUG

floxuridine

Given via hepatic arterial infusion

GENETIC

proteomic profiling

Correlative studies

OTHER

matrix-assisted laser desorption/ionization time of flight mass spectrometry

Correlative studies

OTHER

liquid chromatography

Correlative studies

RADIATION

yttrium Y 90 anti-CEA monoclonal antibody cT84.66

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

mass spectrometry

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

91010

City of Hope, Duarte

All Listed Sponsors
lead

City of Hope Medical Center

OTHER

NCT00645710 - Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery | Biotech Hunter | Biotech Hunter